OPC-67683: all 23 studies that test it
Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.
- Platform Assessing Regimens and Durations In a Global Multisite Consortium for TBRecruitingNCT06114628Phase 2
- Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TuberculosisActive, not recruitingNCT05556746Phase 2Results posted
- Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary TuberculosisCompletedNCT05382312Phase 2Results posted
- Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TBCompletedNCT05221502Phase 2Results posted
- A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary TuberculosisCompletedNCT03678688Phase 1/2Results posted
- Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in Children With MDR-TB With and Without HIVCompletedNCT03141060Phase 1/2Results posted
- Treatment Shortening of MDR-TB Using Existing and New DrugsCompletedNCT02619994Phase 2Results posted
- Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary TuberculosisCompletedNCT02583048Phase 2Results posted
- A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683CompletedNCT02573350Phase 2Results posted
- A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)CompletedNCT01859923Phase 2Results posted
- Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive TuberculosisTerminatedNCT01131351Phase 2Results posted
- A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)CompletedNCT00685360Phase 2Results posted
- Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese CohortActive, not recruitingNCT06649721Phase 3
- Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline CohortActive, not recruitingNCT06081361Phase 3
- Short-course Regimens for the Treatment of Pulmonary TuberculosisActive, not recruitingNCT05766267Phase 2/3
- Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in ChinaStatus unknownNCT04421495Phase 4
- Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)CompletedNCT03896685Phase 3
- Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TBActive, not recruitingNCT03828201Phase 2
- Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis PatientsActive, not recruitingNCT03568383Phase 3
- Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and LevofloxacinWithdrawnNCT02975570Phase 3
- Evaluating Newly Approved Drugs for Multidrug-resistant TBCompletedNCT02754765Phase 3
- Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant TuberculosisCompletedNCT01856634Phase 1
- Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary TuberculosisCompletedNCT00401271Phase 2